Buchumschlag

Gene therapy in transfusion-dependent non-β0/β0 genotype β-thalassemia: first real-world experience of beti-cel

Gene addition and editing strategies for transfusion-dependent β-thalassemia have gained momentum as potentially curative treatment options, with studies showcasing their efficacy and safety. We report, to our knowledge, the first real-world application of betibeglogene autotemcel (beti-cel; Zyntegl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Mirza, Adil (VerfasserIn) , Ritsert, Mona-Lisa (VerfasserIn) , Tao, Gloria (VerfasserIn) , Thakar, Himal (VerfasserIn) , Lobitz, Stephan (VerfasserIn) , Heine, Sabine (VerfasserIn) , Koscher, Leila (VerfasserIn) , Dürken, Matthias (VerfasserIn) , Schmitt, Anita (VerfasserIn) , Schmitt, Michael (VerfasserIn) , Pavel, Petra (VerfasserIn) , Laier, Sascha (VerfasserIn) , Jakoby-Gaide, Donate (VerfasserIn) , Greil, Johann (VerfasserIn) , Kunz, Joachim (VerfasserIn) , Kulozik, Andreas (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 14 January 2025
In: Blood advances
Year: 2025, Jahrgang: 9, Heft: 1, Pages: 29-38
ISSN:2473-9537
DOI:10.1182/bloodadvances.2024014104
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1182/bloodadvances.2024014104
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2473952924006177
Volltext
Verfasserangaben:Adil Mirza, Mona-Lisa Ritsert, Gloria Tao, Himal Thakar, Stephan Lobitz, Sabine Heine, Leila Koscher, Matthias Dürken, Anita Schmitt, Michael Schmitt, Petra Pavel, Sascha Laier, Donate Jakoby, Johann Greil, Joachim Kunz, and Andreas Kulozik
Beschreibung
Zusammenfassung:Gene addition and editing strategies for transfusion-dependent β-thalassemia have gained momentum as potentially curative treatment options, with studies showcasing their efficacy and safety. We report, to our knowledge, the first real-world application of betibeglogene autotemcel (beti-cel; Zynteglo) during its period of active license in Europe from January 2020 to March 2022 for patients aged ≥12 years without a β0/β0 genotype and without a HLA-matched sibling donor, before beti-cel marketing authorization was withdrawn by its holder because of nonsafety reasons. Among 15 screened patients, 4 opted out for fertility and safety concerns, 2 were excluded because of marked hepatic siderosis, and 1 had apheresis collection failure. Eight patients received beti-cel after busulfan myeloablative conditioning, all achieving transfusion independence within 8 to 59 days, with posttreatment hemoglobin levels ranging from 11.3 to 19.3 g/dL. No deaths occurred, but acute toxicity mirrored busulfan’s known effects. Posttreatment platelet management faced challenges because of HLA-antibodies in 3 patients. Monitoring up to month 24 revealed pituitary-gonadal endocrine dysfunction in all 3 female and in 2 of 5 male patients. Additionally, we observed unexpected posttreatment sequelae: 1 patient developed polycythemia that could not be explained by known genetic or acquired mechanisms, 1 patient developed posttreatment depression and anxiety prohibiting her from returning to work, and 1 patient developed fatigue severely compromising both quality of life and work capacity. This real-world experience corroborates beti-cel’s efficacy and safety and provides information on adverse events observed during real-world use of the therapy.
Beschreibung:Online verfügbar: 21. Oktober 2024, Artikelversion: 29. Dezember 2024
Im Titel ist die Zahl 0 bei "non-β0/β0" hochgestellt
Gesehen am 08.05.2025
Beschreibung:Online Resource
ISSN:2473-9537
DOI:10.1182/bloodadvances.2024014104

Ähnliche Einträge